Asapiprant

Drug Profile

Asapiprant

Alternative Names: S-555739

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shionogi
  • Class Acetic acids; Antiallergics; Oxazoles; Piperazines; Small molecules
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Allergic rhinitis

Most Recent Events

  • 07 Aug 2015 Phase-III development is ongoing in Japan and phase-II development in USA and Europe
  • 01 Mar 2013 Shionogi completes a phase II trial in Seasonal allergic rhinitis (combination therapy) in USA (NCT01651871)
  • 31 Jul 2012 Phase-II clinical trials in Allergic rhinitis (Combination therapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top